83% institutional ownership, the selloff was way overdone as the RSI showed. thanks for the cheap shares
Sentiment: Strong Buy
and no PR from the company? dilution coming?
conflict of interest might mean they couldnt make statements at this time about near term plans for launch as it may conflict with what is announced soon, either way. it would seem to indicate that something is very close to being announced but hasnt been finalised but they dont want to be accused of saying one thing now and then something else comes out in the coming days and we all jump up and say "why didnt you tell us that at the conference?"
buy PGNX guaranteed win in the coming months. ARNA is a lot of uncertainty, this may even see 3s at this rate
good work spotting that. hard to be as optimistic as you tho that that is good news. maybe they just dodged the bullets by not appearing
"I'd redirect investors to a company called Galena Biopharma (NASDAQ: GALE ) , which has a newly launched product that treats the same indication."
" However, with proven success in Europe and a market cap of just $200 million, Galena presents a far greater risk/reward ratio versus Insys at $1 billion. If Abstral is successful, Galena could be the second coming of Insys. And as a consequence of success, Abstral might eat away at Subsys' sales, disappointing investors seeking rapid growth. Hence, I'd take profits in shares of Insys."
totally disagree, huge upside potential, limited downside. found support at offering price, the interest in this stock will be immense in the coming months so its almost a no brainer